论文部分内容阅读
近年来我国临床治疗病毒性肝炎取得一些进展,现综述于后。一、慢性肝炎的治疗(一) 群苯双酯:联苯双酯为合成五味子丙素时所得的一种中间产物。经动物实验证明有明显的降低血清谷丙酶的作用,病理改变亦相应减轻。北京地区临床治疗382例(急性肝炎11例,慢迁肝288例,慢活肝75例、肝炎后肝硬化8例),治疗方法:甲组每日3次,每次100mg,连用3月,以后改为每日3次,每次50mg,连用2月。乙组每3日次,每次50mg,连用3月,以后改为每日2次,每次50mg或25mg,每日3次,再用2月。结果:两个治疗组无明显差异,用药1个月后谷丙酶转为正常者
In recent years, some progress has been made in clinical treatment of viral hepatitis in our country. First, the treatment of chronic hepatitis (a) Qubeidide: Bifendate is an intermediate product of the synthesis of Schisandrins. Animal experiments show that there is a clear role in reducing serum glutathione, pathological changes are also reduced accordingly. 382 cases of clinical treatment in Beijing (acute hepatitis in 11 cases, 288 cases of slow-moving liver, 75 cases of slow-living liver, liver cirrhosis in 8 cases), treatment group A three times a day, each 100mg, once every 3 months, Later changed to 3 times a day, each 50mg, once every February. Group B every 3 days, each 50mg, once every 3 months, later changed to 2 times a day, each time 50mg or 25mg, 3 times a day, then February. Results: There was no significant difference between the two treatment groups. One month after the administration, the enzyme was changed to normal